Click here to close now.


News Feed Item

2013 US Hospital Cancer Diagnostics Market

NEW YORK, Jan. 4, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

2013 US Hospital Cancer Diagnostics Market

This new report from Venture Planning Group contains 567 pages, 50 tables, and presents a comprehensive analysis of the US hospital cancer diagnostics market, including: 

  • Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next 5 years. 
  • Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. 
  • Test volume and sales forecasts for 40 cancer diagnostic procedures performed in US hospitals.  
  • Current instrumentation technologies and feature comparison of leading analyzers. 
  • Sales and market shares of  leading suppliers. 
  • Emerging diagnostic technologies and their potential market applications. 
  • Product development opportunities. 
  • Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. 
  • Business opportunities and strategic recommendations for suppliers. 

         Contains 567 pages and 50 tables

Table of Contents


Worldwide Market and Technology Overview

A. Cancer Statistics and Etiology

1. Brest Cancer

2. Lung Cancer

3. Colon and Rectum Cancer

4. Prostate Cancer

5. Stomach Cancer

6. Leukemia

7. Lymphoma

8. Oral Cancer

9. Skin Cancer

10. Uterine Cancer

11. Ovarian Cancer

12. Bladder Cancer

B. Major Current And Emerging Cancer Diagnostic Tests

1. Introduction

2. Tumor Marker Classification


4. Alpha-Fetoprotein (AFP)

5. Beta-2 Microglobulin

6. CA 15-3/27.29

7. CA 19-9

8. CA-125

9. Calcitonin

10. Carcinoembrionic Antigen (CEA)

11. Estrogen and Progesterone Receptors

12. Ferritin

13. Gastrin

14. Human Chorionic Gonadotropin (HCG)

15. Insulin

16. NSE

17. Occult Blood

18. PAP Smear/HPV

19. Prostatic Acid Phosphatase (PAP)

20. Prostate-Specific Antigen (PSA)

21. Squamous Cell Carcinoma Antigen (SCC)

22. T and B Lymphocytes

23. TdT

24. Thyroglobulin

25. Tissue Polypeptide Antigen (TPA)

26. Biochemical Tumor Markers


- B-Protein


- 5'-Nucleotidase

27. Oncogenes

- Abl/abl-bcr

- AIB1

- BCL-2


- CD44

- C-fos

- C-myb

- C-myc

- CYP-17

- Erb-B

- HPC1

- N-myc

- P40

- P51

- P53


- PTI-1

- Ras

- Reg

- Sis

- Src

28. Polypeptide Growth Factors

- Basic Fibroblast Growth Factor

- Beta-TGF

- Cachectin (TNT)

- Calmodulin


- Nerve Growth Factor (NGF)

- Epidermal Growth Factor (EGF)

- Ornithine Decarboxylase

- Transferrin

- Transforming Growth Factor-Alpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

- Alpha-Interferon

- B Cell Growth Factors

- B Cell Growth Factor (BCGF)

- Gamma-Interferon

- Interleukin-1 (IL-1)

- Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Tumor Markers

- N-Acetylglucosamine

- Actin

- Alpha-Actin

- Antineuronal Antibodies

- 7B2

- B72.3

- Bax

- BCD-F9

- BLCA-4

- Blood Group Antigens A,B,H

- CA 50

- CA 72-4/TAG-72

- CA 195

- CA-242

- CA-549

- CAM 26

- CAR-3

- Cathepsin-D

- Chromogranin A and B

- Cluster 1 Antigen

- Cluster-5/5A Antigen


- CU18

- DR-70

- DU-PAN-2

- Endometrial Bleeding Associated Factor

- Endostatin

- Epithelial Membrane Antigen

- Feulgen Hydrolysis

- Fibronectin


- (1->3)-L-fucosyltransferase

- Gastrin-Releasing Peptide (GRP)

- GDCFP-15

- Glucagon

- Glycoamines

- H23

- Her-2

- Human Carcinoma Antigen


- HSP27

- Intermediate Filaments

- Cytokeratins/CK18/Cyfra 21-1

- Desmin

- Gliofibrillary Acid Protein

- Neurofilaments

- Vimentin

- KA 93

- Kinases

- KP16D3


- Leukocyte Common Antigen

- Lewis Antigens

- Lysophosphatidic Acid (LPA)

- Ma 695/Ma 552



- ME1

- Minactivin

- MN/CA9


- Mucin Cancer Antigen (MCA)

- Multiple Tumor Suppressor 1

- Myosin

- NEA-130

- NMP22

- OA-519

- Opiod Peptides

- P-glycoprotein

- Pancreatic Oncofetal Antigen (POA)

- Placental Lactogen

- PR92

- Proliferative Index, Ki-67

- Px

- RB Inactivation/Deletion

- Ret

- SCCL 175

- Selectin

- Sialic Acid

- Sialyl SSEA-1/SLX

- SN10

- Somatostatin

- TA-90


- Tachykinin

- TAG 12


- Troponin

- Tubulin



- Villen

C. Instrumentation Review

And Market Needs

1. Abbott AxSYM

2. Abbott Architect c4000

3. Abbott Architect i2000 Series

4. Abbott Architect ci8200 System

5. Beckman Coulter UniCel Series

6. Beckman Coulter Access

7. Binding Site ESP600

8. bioMerieux Mini Vidas

9. Carolina Chemistries BioLis 24i

10. DiaSorin Liaison

11. Horiba ABX Pentra 400

12. Inverness DS2

13. J&J Vitros ECi/ECiQ

14. J&J Vitros 3600

15. J&J Vitros 5600

16. Olympus AU5400

17. Olympus AU3000i

18. Olympus AU2700

19. Roche Modular Analytics

20. Roche Cobas Integra 400

21. Roche Cobas Integra 400 Plus

22. Roche Elecsys

23. Roche Cobas c311

24. Siemens ADVIA Centaur

25. Siemens Dimension

26. Siemens Dimension RxL Max

27. Siemens Dimension Vista 500

28. Siemens Immulite

29. Siemens Stratus

30. Tosoh AIA-Series

31. Vital Diagnostics ATAC 8000

32. Vital Diagnostics Envoy 500

D. Current and Emerging Technologies

1. Monoclonal and Polyclonal Antibodies

2. Immunoassays

a. Technological Principle

b. Radioimmunoassay (RIA)

c. Enzyme Immunoassays (EIA)

- Overview


- Immunofiltration

- Particle-Membrane Capture Immunoassay

- Enzyme Amplification

d. Fluorescent Immunoassays

e. Luminescence

- Chemiluminescence

- Bioluminescence

f. Latex Agglutination

g. Immunoprecipitation

H. Affinity Chromatographu

e. Liposome Flow-Injection Immunoassay

3. Molecular Diagnostics

a. Technology Overview

b. Amplification Methods



- Immuno-PCR









- 3 SR, and others

4. Chromosome Analysis

a. Chronic Myelogenous Leukemia (CML)

b. Acute Myeloid Leukemia (AML)

c. Acute Lymphoblastic Leukemia (ALL)

d. Malignant Lymphomas

Lymphoid Malignancies

e. Chronic Lymphocytic Leukemia (CLL)

f. Solid Cancers

g. Chromosomal Translocation and Oncogenes

5. Artificial Intelligence

6. Flow Cytometry

7. Two Dimensional Gel Electrophoresis (2-DGE)

8. Biosensors

9. Competing/Complementing Technologies

a. CT

b. MRI

c. NMR

d. PET

e. Photonics Spectroscopy

E. Personal Testing


A. Executive Summary

B. Business Environment

1. Health Care Expenditures

2. Cost Consciousness

3. Industry Consolidation

4. Managed Care

5. Hospitals

6. Admissions

7. Length of Stay

8. Industry Diversification

9. Physician Demographics

10. Population Aging

a. Chronic Illness

b. Disease Incidence

c. Susceptibility to Iatrogenesis

d. Multiple Illness Cases

11. Laboratory Regulations

C. Market Structure

1. Centralized Testing

a. Hospitals

b. Commercial/Private Laboratories

2. POT/Decentralized Testing

a. Physician Offices/Group Practices

b. Cancer Clinics

c. Point-Of-Care Testing

d. Other Decentralized Testing Locations

D. Market Size, Growth and Major Suppliers Sales,

Instrument Placements and Market Shares

Major Product Development Opportunities

A. Reagent Kits and Test Systems/Panels

B. Instrumentation

C. Computers, Software and Automation

D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

A. Internal Development

B. Collaborative Arrangements

C. University Contracts

D. Distribution Strategies

1. Marketing Approaches

2. Product Complexity

3. Customer Preference

4. Established Suppliers

5. Emerging Suppliers

6. Major Types of Distributors

7. Market Segmentation Factor

Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

Competitive Profiles

- Abbott

- AdnaGen

- Applied Gene Technologies

- Arca

- Beckman Coulter/Danaher

- Becton Dickinson

- Biomedical Diagnostics

- bioMerieux

- Bio-Rad

- Cepheid

- Correlogic Systems

- Dako

- Decode

- Diadexus

- Diagnocure

- Diasorin

- Eiken Chemical

- Enterix

- Enzo Biochem

- Epigenomics

- Exact Sciences

- Fujirebio

- Gen-Probe

- Guided Therapeutics

- Hologic

- Ipsogen

- Kreatech

- Kyowa Medex

- Life Technologies

- Mackay Life Sciences

- Myriad Genetics

- Nanogen Elitech

- OncoLab

- Otho-Clinical Diagnostics

- Panacea Pharmaceuticals

- Polartechnics

- Polymedco

- PreMD

- Qiagen

- Radient Pharmaceuticals

- Roche

- Scienion

- Sequenom

- Siemens Healthcare

- Takara Bio

- Targeted Diagnostics & Therapeutics

- Tosoh

- Veridex

- Wako Pure Chemicals

- Wallac/PE

- Zila

List of Tables

Tumor Marker Classification

Major Companies Developing or Marketing

ACTH Tests

Major Companies Developing or Marketing

AFP Tests

Major Companies Developing or Marketing

Beta-2 Microglobulin Tests

Major Companies Developing or Marketing

CA 15-3/27.29 Tests

Major Companies Developing or Marketing

CA 19-9 Tests

Major Companies Developing or Marketing

CA 125 Tests

Major Companies Developing or Marketing

Calcitonin Tests

Major Companies Developing or Marketing

CEA Tests

Major Companies Developing or Marketing

Estrogen Receptor Tests

Major Companies Developing or Marketing

Progesterone Receptor Tests

Major Companies Developing or Marketing

Ferritin Tests

Major Companies Developing or Marketing

Gastrin Tests

Major Companies Developing or Marketing

HCG Tests

Major Companies Developing or Marketing

Insulin Tests

Major Companies Developing or Marketing

NSE Tests

Major Companies Developing or Marketing

Occult Blood Tests

Major Companies Developing or Marketing

PAP Smear/HPV Tests

Major Companies Developing or Marketing

PAP Tests

Major Companies Developing or Marketing

PSA Tests

Major Companies Developing or Marketing

Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications

In Cancer Diagnosis

Oncogenes Potential Applications

In Cancer Diagnosis

Major Companies Developing or Marketing

Oncogene Tests

Growth Factors Potential Applications

In Cancer Diagnosis

Colony Stimulating Factors Potential

Applications in Cancer Diagnosis

Lymphokines Potential Applications

In Cancer Diagnosis

Immunohistochemical Stains Potential

Applications in Cancer Diagnosis

Executive Summary Table: U.S., Hospital

Cancer Diagnostic Test Volume and Sales Forecast

U.S., Estimated New Cancer Cases and Deaths

U.S., Estimated Cancer Death Rates

Per 100,000 Population

U.S., Laboratories Performing Cancer Diagnostic


U.S., Hospital Laboratories Performing

Cancer Diagnostics Tests by Bed Size

U.S., Hospital Laboratories Major Cancer

Diagnostic Test Volume Forecast by Test

U.S., Total Cancer Diagnostics Sales

By Major Supplier

U.S., ACTH Testing Market Diagnostics

Sales by Major Supplier

U.S., AFP Testing Market Diagnostics

Sales by Major Supplier

U.S., Beta-2 Migroblolulin Testing Market

Diagnostics Sales by Major Supplier

U.S., CA 15-3/27.29 Testing Market

Diagnostics Sales by Major Supplier

U.S., CA 19-9 Testing Market Diagnostics

Sales by Major Supplier

U.S., CA 125 Testing Market Diagnostics

Sales by Major Supplier

U.S., CEA Testing Market Diagnostics

Sales by Major Supplier

U.S., Ferritin Testing Market

Diagnostics Sales by Major Supplier

U.S., HCG Testing Market

Diagnostics Sales by Major Supplier

U.S., Insulin Testing Market

Diagnostics Sales by Major Supplier

U.S., Parathyroid Hormone Testing

Market Diagnostics Sales by Major Supplier

U.S., PAP Testing Market Diagnostics

Sales by Major Supplier

U.S., Progesterone Receptor Testing Market

Diagnostics Sales by Major Supplier

U.S., PSA Testing Market Diagnostics

Sales by Major Supplier

To order this report:

Diagnostics Industry: 2013 US Hospital Cancer Diagnostics Market

Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Saviynt Inc. has announced the availability of the next release of Saviynt for AWS. The comprehensive security and compliance solution provides a Command-and-Control center to gain visibility into risks in AWS, enforce real-time protection of critical workloads as well as data and automate access life-cycle governance. The solution enables AWS customers to meet their compliance mandates such as ITAR, SOX, PCI, etc. by including an extensive risk and controls library to detect known threats and b...
DevOps and Continuous Delivery software provider XebiaLabs has announced it has been selected to join the Amazon Web Services (AWS) DevOps Competency partner program. The program is designed to highlight software vendors like XebiaLabs who have demonstrated technical expertise and proven customer success in DevOps and specialized solution areas like Continuous Delivery. DevOps Competency Partners provide solutions to, or have deep experience working with AWS users and other businesses to help t...
SYS-CON Events announced today that Spirent Communications, the leader in testing navigation and positioning systems, will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Spirent Communications enables innovations in communications technologies that help connect people. Whether it is service provider, data centers, enterprise IT networks, mobile communications, connected vehicles or the Inte...
SYS-CON Events announced today that Luxoft Holding, Inc., a leading provider of software development services and innovative IT solutions, has been named “Bronze Sponsor” of SYS-CON's @ThingsExpo, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Luxoft’s software development services consist of core and mission-critical custom software development and support, product engineering and testing, and technology consulting.
WebRTC is about the data channel as much as about video and audio conferencing. However, basically all commercial WebRTC applications have been built with a focus on audio and video. The handling of “data” has been limited to text chat and file download – all other data sharing seems to end with screensharing. What is holding back a more intensive use of peer-to-peer data? In her session at @ThingsExpo, Dr Silvia Pfeiffer, WebRTC Applications Team Lead at National ICT Australia, will look at di...
NHK, Japan Broadcasting, will feature the upcoming @ThingsExpo Silicon Valley in a special 'Internet of Things' and smart technology documentary that will be filmed on the expo floor between November 3 to 5, 2015, in Santa Clara. NHK is the sole public TV network in Japan equivalent to the BBC in the UK and the largest in Asia with many award-winning science and technology programs. Japanese TV is producing a documentary about IoT and Smart technology and will be covering @ThingsExpo Silicon Val...
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. Migration to cloud shifts computing resources from your data center, which can yield significant advantages provided that the cloud vendor an offer enterprise-grade quality for your application.
The APN DevOps Competency highlights APN Partners who demonstrate deep capabilities delivering continuous integration, continuous delivery, and configuration management. They help customers transform their business to be more efficient and agile by leveraging the AWS platform and DevOps principles.
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
Internet of Things (IoT) will be a hybrid ecosystem of diverse devices and sensors collaborating with operational and enterprise systems to create the next big application. In their session at @ThingsExpo, Bramh Gupta, founder and CEO of, and Fred Yatzeck, principal architect leading product development at, discussed how choosing the right middleware and integration strategy from the get-go will enable IoT solution developers to adapt and grow with the industry, while at th...
Developing software for the Internet of Things (IoT) comes with its own set of challenges. Security, privacy, and unified standards are a few key issues. In addition, each IoT product is comprised of at least three separate application components: the software embedded in the device, the backend big-data service, and the mobile application for the end user's controls. Each component is developed by a different team, using different technologies and practices, and deployed to a different stack/...
Through WebRTC, audio and video communications are being embedded more easily than ever into applications, helping carriers, enterprises and independent software vendors deliver greater functionality to their end users. With today’s business world increasingly focused on outcomes, users’ growing calls for ease of use, and businesses craving smarter, tighter integration, what’s the next step in delivering a richer, more immersive experience? That richer, more fully integrated experience comes ab...
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. It also ensured scalability and better service for customers, including MUY! Companies, one of the country's largest franchise restaurant companies with 232 Pizza Hut locations. This is one example of...
Between the compelling mockups and specs produced by analysts, and resulting applications built by developers, there exists a gulf where projects fail, costs spiral, and applications disappoint. Methodologies like Agile attempt to address this with intensified communication, with partial success but many limitations. In his session at DevOps Summit, Charles Kendrick, CTO and Chief Architect at Isomorphic Software, will present a revolutionary model enabled by new technologies. Learn how busine...
JFrog has announced a powerful technology for managing software packages from development into production. JFrog Artifactory 4 represents disruptive innovation in its groundbreaking ability to help development and DevOps teams deliver increasingly complex solutions on ever-shorter deadlines across multiple platforms JFrog Artifactory 4 establishes a new category – the Universal Artifact Repository – that reflects JFrog's unique commitment to enable faster software releases through the first pla...